|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries. CA Cancer J
Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
European Association for the Study of the
Liver, . EASL Clinical Practice Guidelines: Management of
hepatocellular carcinoma. J Hepatol. 69:182–236. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhou F, Shang W, Yu X and Tian J:
Glypican-3: A promising biomarker for hepatocellular carcinoma
diagnosis and treatment. Med Res Rev. 38:741–767. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Harding JJ, Khalil DN and Abou-Alfa GK:
Biomarkers: What role do they play (If Any) for diagnosis,
prognosis and tumor response prediction for hepatocellular
carcinoma? Dig Dis Sci. 64:918–927. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang Y and Wan YY: Golgi protein 73,
hepatocellular carcinoma and other types of cancers. Liver Res.
4:161–167. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang X, Zhang Y, Yang N, He H, Tao X, Kou
C and Jiang J: Evaluation of the combined application of AFP,
AFP-L3%, and DCP for hepatocellular carcinoma diagnosis: A
Meta-analysis. Biomed Res Int. 2020:50876432020.PubMed/NCBI
|
|
7
|
Zhu M, Zheng J, Wu F, Kang B, Liang J,
Heskia F, Zhang X and Shan Y: OPN is a promising serological
biomarker for hepatocellular carcinoma diagnosis. J Med Virol. Feb
11–2021.(Epub ahead of print). doi: 10.1002/jmv.25704.
|
|
8
|
Yan Z, Zhou Z, Li C, Yang X, Yang L, Dai
S, Zhao J, Ni H, Li S and Yao Y: Polymorphisms in miRNA genes play
roles in the initiation and development of cervical cancer. J
Cancer. 10:4747–4753. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ryan BM: microRNAs in cancer
susceptibility. Adv Cancer Res. 135:151–171. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zóia MA, Azevedo FV, Vecchi L, Mota ST,
Rodovalho VR, Cordeiro AO, Correia LI, Silva AC, Ávila VM, Araújo
TG and Goulart LR: Inhibition of triple-negative breast cancer cell
aggressiveness by cathepsin D blockage: Role of Annexin A1. Int J
Mol Sci. 20:13372019. View Article : Google Scholar
|
|
11
|
Farokhizadeh Z, Dehbidi S, Geramizadeh B,
Yaghobi R, Malekhosseini SA, Behmanesh M, Sanati MH, Afshari A,
Moravej A and Karimi MH: Association of MicroRNA polymorphisms with
hepatocellular carcinoma in an iranian population. Ann Lab Med.
39:58–66. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Akkız H, Bayram S, Bekar A, Akgöllü E and
Ulger Y: A functional polymorphism in pre-microRNA-196a-2
contributes to the susceptibility of hepatocellular carcinoma in a
Turkish population: A case-control study. J Viral Hepat.
18:e399–e407. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tian T, Wang M, Zhu W, Dai ZM, Lin S, Yang
PT, Liu XH, Liu K, Zhu YY, Zheng Y, et al: MiR-146a and miR-196a-2
polymorphisms are associated with hepatitis virus-related
hepatocellular cancer risk: A meta-analysis. Aging (Albany NY).
9:381–392. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Han Y, Pu R, Han X, Zhao J, Zhang Y, Zhang
Q, Yin J, Xie J, Shen Q, Deng Y, et al: Associations of
pri-miR-34b/c and pre-miR-196a2 polymorphisms and their
multiplicative interactions with hepatitis B virus mutations with
hepatocellular carcinoma risk. PLoS One. 8:e585642013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim HY, Yoon JH, Lee HS, Cheong JY, Cho
SW, Shin HD and Kim YJ: MicroRNA-196A-2 polymorphisms and
hepatocellular carcinoma in patients with chronic hepatitis B. J
Med Virol. 86:446–453. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li XD, Li ZG, Song XX and Liu CF: A
variant in microRNA-196a2 is associated with susceptibility to
hepatocellular carcinoma in Chinese patients with cirrhosis.
Pathology. 42:669–673. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Riazalhosseini B, Mohamed Z, Apalasamy YD,
Eng HS and Mohamed R: Association between microRNA-196A2 and
microRNA-146A polymorphisms and progression to cirrhosis and
hepatocellular carcinoma in patients with viral hepatitis B.
Pharmacogenet Genomics. 26:74–79. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kou JT, Fan H, Han D, Li L, Li P, Zhu J,
Ma J, Zhang ZH and He Q: Association between four common microRNA
polymorphisms and the risk of hepatocellular carcinoma and HBV
infection. Oncol Lett. 8:1255–1260. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kang Z, Li Y, He X, Jiu T, Wei J, Tian F
and Gu C: Quantitative assessment of the association between
miR-196a2 rs11614913 polymorphism and cancer risk: Evidence based
on 45,816 subjects. Tumour Biol. 35:6271–6282. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu JY, Hu F, Du W, Ma XL and Yuan K: Study
of the association between five polymorphisms and risk of
hepatocellular carcinoma: A meta-analysis. J Chin Med Assoc.
80:191–203. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng L, Zhuang C, Zhao J and Ming L:
Functional miR-146a, miR-149, miR-196a2 and miR-499 polymorphisms
and the susceptibility to hepatocellular carcinoma: An updated
meta-analysis. Clin Res Hepatol Gastroenterol. 41:664–676. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qi JH, Wang J, Chen J, Shen F, Huang JT,
Sen S, Zhou X and Liu SM: High-resolution melting analysis reveals
genetic polymorphisms in microRNAs confer hepatocellular carcinoma
risk in Chinese patients. BMC Cancer. 14:6432014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qiu GP and Liu J: MicroRNA gene
polymorphisms in evaluating therapeutic efficacy after
transcatheter arterial chemoembolization for primary hepatocellular
carcinoma. Genet Test Mol Biomarkers. 205:579–586. 2016. View Article : Google Scholar
|
|
24
|
Xu X, Ling Q, Wang J, Xie H, Wei X, Lu D,
Hu Q, Zhang X, Wu L, Zhou L and Zheng S: Donor miR-196a-2
polymorphism is associated with hepatocellular carcinoma recurrence
after liver transplantation in a Han Chinese population. Int J
Cancer. 138:620–629. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bhaumik D, Scott GK, Schokrpur S, Patil
CK, Campisi J and Benz CC: Expression of microRNA-146 suppresses
NF-kappaB activity with reduction of metastatic potential in breast
cancer cells. Oncogene. 27:5643–5647. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang Z, Zhang L, Shi X, Xu H, Wang T and
Bian J: Association between two common polymorphisms and risk of
hepatocellular carcinoma: Evidence from an updated meta-analysis.
Biomed Res Int. 2014:4686052014.PubMed/NCBI
|
|
27
|
Wang BS, Liu Z, Xu WX and Sun SL:
Functional polymorphisms in microRNAs and susceptibility to liver
cancer: A meta-analysis and meta-regression. Genet Mol Res.
13:5426–5440. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hu M, Zhao L, Hu S and Yang J: The
association between two common polymorphisms in MicroRNAs and
hepatocellular carcinoma risk in Asian population. PLoS One.
8:e570122013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wei W, Hu Z, Fu H, Tie Y, Zhang H, Wu Y
and Zheng X: MicroRNA-1 and microRNA-499 downregulate the
expression of the ets1 proto-oncogene in HepG2 cells. Oncol Rep.
28:701–706. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim WH, Min KT, Jeon YJ, Kwon CI, Ko KH,
Park PW, Hong SP, Rim KS, Kwon SW, Hwang SG, et al: Association
study of microRNA polymorphisms with hepatocellular carcinoma in
Korean population. Gene. 504:92–97. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ma Y, Wang R, Zhang J, Li W, Gao C, Liu J
and Wang J: Identification of miR-423 and miR-499 polymorphisms on
affecting the risk of hepatocellular carcinoma in a large-scale
population. Genet Test Mol Biomarkers. 18:516–524. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Luo G, Chao YL, Tang B, Li BS, Xiao YF,
Xie R, Wang SM, Wu YY, Dong H, Liu XD, et al: miR-149 represses
metastasis of hepatocellular carcinoma by targeting
actin-regulatory proteins PPM1F. Oncotarget. 6:37808–37823. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang R, Zhang J, Ma Y, Chen L, Guo S,
Zhang X, Ma Y, Wu L, Pei X, Liu S, et al: Association study of
miR-149 rs2292832 and miR-608 rs4919510 and the risk of
hepatocellular carcinoma in a large-scale population. Mol Med Rep.
10:2736–2744. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Roy S, Levi E, Majumdar AP and Sarkar FH:
Expression of miR-34 is lost in colon cancer which can be
re-expressed by a novel agent CDF. J Hematol Oncol. 5:582012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Son MS, Jang MJ, Jeon YJ, Kim WH, Kwon CI,
Ko KH, Park PW, Hong SP, Rim KS, Kwon SW, et al: Promoter
polymorphisms of pri-miR-34b/c are associated with hepatocellular
carcinoma. Gene. 524:156–160. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu CJ, Ma XW, Zhang XJ and Shen SQ:
pri-miR-34b/c rs4938723 polymorphism is associated with
hepatocellular carcinoma risk: A case-control study in a Chinese
population. Int J Mol Epidemiol Genet. 8:1–7. 2017.PubMed/NCBI
|
|
37
|
Luna JM, Barajas JM, Teng KY, Sun HL,
Moore MJ, Rice CM, Darnell RB and Ghoshal K: Argonaute CLIP defines
a deregulated miR-122-bound transcriptome that correlates with
patient survival in human liver cancer. Mol Cell. 67:400–410.e7.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bei C, Liu S, Yu X, Qiu M, Tang B, Liao W,
He S and Yu H: Single nucleotide polymorphisms in miR-122 are
associated with the risk of hepatocellular carcinoma in a southern
Chinese population. Biomed Res Int. 2018:15402012018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu Y, Xie K, Wen J, Deng M, Li J and Hu
Z: A genetic variant in microRNA-122 regulatory region confers risk
for chronic hepatitis B virus infection and hepatocellular
carcinoma in Han Chinese. J Med Virol. 86:1669–1674. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang T, Xu L, Jia R and Wei J: MiR-218
suppresses the metastasis and EMT of HCC cells via targeting
SERBP1. Acta Biochim Biophys Sin (Shanghai). 49:383–391. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Han Y, Pu R, Han X, Zhao J, Li W, Yin J,
Zhang Y, Shen Q, Xie J, Zhang Q, et al: Association of a potential
functional pre-miR-218 polymorphism and its interaction with
hepatitis B virus mutations with hepatocellular carcinoma risk.
Liver Int. 34:728–736. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang LS, Liang WB, Gao LB, Li HY, Li LJ,
Chen PY, Liu Y, Chen TY, Han JG, Wei YG and Zhang L: Association
between pri-miR-218 polymorphism and risk of hepatocellular
carcinoma in a Han Chinese population. DNA Cell Biol. 31:761–765.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Qi F, Huang M, Pan Y, Liu Y, Liu J, Wen J,
Xie K, Shen H, Ma H, Miao Y and Hu Z: A genetic variant in the
promoter region of miR-106b-25 cluster predict clinical outcome of
HBV-related hepatocellular carcinoma in Chinese. PLoS One.
9:e853942014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu Y, Zhang Y, Wen J, Liu L, Zhai X, Liu
J, Pan S, Chen J, Shen H and Hu Z: A genetic variant in the
promoter region of miR-106b-25 cluster and risk of HBV infection
and hepatocellular carcinoma. PLoS One. 7:e322302012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
An J, Liu J, Liu L, Liu Y, Pan Y, Huang M,
Qi F, Wen J, Xie K, Ma H, et al: A genetic variant in primary
miR-378 is associated with risk and prognosis of hepatocellular
carcinoma in a Chinese population. PLoS One. 9:e937072014.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Cheong JY, Shin HD, Cho SW and Kim YJ:
Association of polymorphism in microRNA 604 with susceptibility to
persistent hepatitis B virus infection and development of
hepatocellular carcinoma. J Korean Med Sci. 29:1523–1527. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kwak MS, Lee DH, Cho Y, Cho EJ, Lee JH, Yu
SJ, Yoon JH, Lee HS, Kim CY, Cheong JY, et al: Association of
polymorphism in pri-microRNAs-371-372-373 with the occurrence of
hepatocellular carcinoma in hepatitis B virus infected patients.
PLoS One. 7:e419832012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li W, Ma Y, Zeng D, Zhang J, Wang R, Hu J,
Yang D, Hu H, Wang J and Liu J: Association between microRNA single
nucleotide polymorphisms and the risk of hepatocellular carcinoma.
Rev Med Chil. 144:508–515. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Min P, Li W, Zeng D, Ma Y, Xu D, Zheng W,
Tang F, Chen J, Shi J, Hu H, et al: A single nucleotide variant in
microRNA-1269a promotes the occurrence and process of
hepatocellular carcinoma by targeting to oncogenes SPATS2L and
LRP6. Bull Cancer. 104:311–320. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang Q, Yu X, Li Q, Qin L, Tan S, Zeng X,
Qiu X, Tang B, Jin J, Liao W, et al: Association between miR-199a
rs74723057 and MET rs1621 polymorphisms and the risk of
hepatocellular carcinoma. Oncotarget. 7:79365–79371. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang C, Li L, Yin Z, Zhang Q, Zhao H, Tao
R, Wang S, Hu S, He Y, Wang D, et al: An indel polymorphism within
pre-miR3131 confers risk for hepatocellular carcinoma.
Carcinogenesis. 38:168–176. 2017.PubMed/NCBI
|
|
52
|
He L, Meng D, Zhang SH, Zhang Y, Deng Z
and Kong LB: microRNA-608 inhibits human hepatocellular carcinoma
cell proliferation via targeting the BET family protein BRD4.
Biochem Biophys Res Commun. 501:1060–1067. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Dai ZM, Lv JR, Liu K, Lei XM, Li W, Wu G,
Liu XH, Zhu YX, Hao Q and Dai ZJ: The role of microRNA-608
polymorphism on the susceptibility and survival of cancer: A
meta-analysis. Aging (Albany NY). 10:1402–1414. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yu G, Xiao Q, Ma XP, Chen X, Shi Z, Zhang
LY, Chen H, Zhang P, Ding DL, Huang HX, et al: miR-492G>C
polymorphism (rs2289030) is associated with overall survival of
hepatocellular carcinoma patients. Tumour Biol. 37:8961–8972. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Long XD, Huang XY, Yao JG, Liao P, Tang
YJ, Ma Y and Xia Q: Polymorphisms in the precursor microRNAs and
aflatoxin B1-related hepatocellular carcinoma. Mol Carcinog.
55:1060–1072. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ji J, Xu M, Tu J, Zhao Z, Gao J, Chen M,
Song J, Zhu H, Cheng X, Hui J, et al: MiR-155 and its functional
variant rs767649 contribute to the susceptibility and survival of
hepatocellular carcinoma. Oncotarget. 7:60303–60309. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wei HX, Tian GX, Song JK, Yang LJ and Wang
YP: The association between rs16917496 T/C polymorphism of SET8
gene and cancer risk in Asian populations: A meta-analysis. Biosci
Rep. 38:BSR201807022018. View Article : Google Scholar : PubMed/NCBI
|
